Early Improvement of Psychiatric Symptoms with Long-Acting Injectable Antipsychotic Predicts Subsequent Social Functional Remission in Patients with Schizophrenia

References

• Nasrallah HA, Targum SD, Tandon R, et al. Defining and measuring clinical effectiveness in the treatment of schizophrenia. Psychiatr Serv. 2005;56:273–282. doi:10.1176/appi.ps.56.3.27315746501
   PubMed Web of Science ®Google Scholar
• Yeomans D, Taylor M, Currie A, et al. Resolution and remission in schizophrenia: getting well and staying well. Adv Psychiatr Treat. 2010;16:86–95. doi:10.1192/apt.bp.108.006411
   Google Scholar
• Lieberman JA, Malaspina D, Jarskog LF. Preventing clinical deterioration in the course of schizophrenia: the potential for neuroprotection. CNS Spectr. 2006;11(Suppl 4):1–13.
   Web of Science ®Google Scholar
• Larnbert M, Naber D. Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life. CNS Drugs. 2004;18:1–13.
   Web of Science ®Google Scholar
• Duțescu MM, Popescu RE, Balcu L, et al. Social functioning in schizophrenia clinical correlations. Curr Health Sci J. 2018;44(2):151‐156. doi:10.12865/CHSJ.44.02.10
   Google Scholar
• Haro JM, Novick D, Suarez D, et al. Predictors of the course of illness in outpatients with schizophrenia: a prospective three year study. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:1287–1292.18502012
   PubMed Web of Science ®Google Scholar
• Lambert M, Schimmelmann BG, Naber D, et al. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. J Clin Psychiatry. 2006;67(11):1690‐1697. doi:10.4088/JCP.v67n1104
   Web of Science ®Google Scholar
• Spellmann I, Riedel M, Schennach R, et al. One-year functional outcomes of naturalistically treated patients with schizophrenia. Psychiatry Res. 2012;198(3):378–385. doi:10.1016/j.psychres.2011.12.04722421065
   PubMed Web of Science ®Google Scholar
• Schennach-Wolff R, Jäger M, Seemüller F, et al. Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders. Schizophr Res. 2009;113(2–3):210–217.19560901
   PubMed Web of Science ®Google Scholar
• Lambert M, Naber D, Schacht A, et al. Rates and predictors of remission and recovery during 3 years in 392 never-treated patients with schizophrenia. Acta Psychiatr Scand. 2008;118(3):220–229. doi:10.1111/j.1600-0447.2008.01213.x18699954
   PubMed Web of Science ®Google Scholar
• Mortimer AM. Symptom rating scales and outcome in schizophrenia. Br J Psychiatry Suppl. 2007;50:S7–S14. doi:10.1192/bjp.191.50.s718019038
   PubMedGoogle Scholar
• European Medicines Agency. Guideline on clinical investigation of medicinal products, including depot preparations in the treatment of schizophrenia. Available from:http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/10/WC500133437.pdf. Accessed 122, 2015.
   Google Scholar
• Lehman AF. Developing an outcomes-oriented approach for the treatment of schizophrenia. J Clin Psychiatry. 1999;60(Suppl 19):S30–S35.
   Google Scholar
• Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162(3):441–449. doi:10.1176/appi.ajp.162.3.44115741458
   PubMed Web of Science ®Google Scholar
• Lipkovich IA, Deberdt W, Csernansky JG, et al. Defining “good” and “poor” outcomes in patients with schizophrenia or schizoaffective disorder: a multidimensional data-driven approach. Psychiatry Res. 2009;170:161–167. doi:10.1016/j.psychres.2008.09.00419897252
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Nyhuis AW, Faries DE, et al. Clinical, functional and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophr Bull. 2008;34(6):1163–1171. doi:10.1093/schbul/sbm13418156640
   PubMed Web of Science ®Google Scholar
• Kinon BJ, Chen L, Ascher-Svanum H, et al. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology. 2010;35:581–590. doi:10.1038/npp.2009.16419890258
   PubMed Web of Science ®Google Scholar
• Leucht S, Shamsi SA, Busch R, et al. Predicting antipsychotic drug response - replication and extension to six weeks in an international olanzapine study. Schizophr Res. 2008;101(1–3):312–319. doi:10.1016/j.schres.2008.01.01818308513
   PubMed Web of Science ®Google Scholar
• Nakagawa R, Ohnishi T, Kobayashi H, et al. The social functional outcome of being naturalistically treated with paliperidone extended-release in patients with schizophrenia. Neuropsychiatr Dis Treat. 2015;22(11):1511–1521.
   Google Scholar
• Gorwood P, Bouju S, Deal C, et al. Predictive factors of functional remission in patients with early to mid-stage schizophrenia treated by long acting antipsychotics and the specific role of clinical remission. Psychiatry Res. 2019;281:112560. doi:10.1016/j.psychres.2019.11256031521843
   PubMed Web of Science ®Google Scholar
• Savitz AJ, Xu H, Gopal S, et al. Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter,double-blind, noninferiority study. Int J Neuropsychopharmacol. 2016;19:7. doi:10.1093/ijnp/pyw018
   Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261‐276. doi:10.1093/schbul/13.2.261
   Web of Science ®Google Scholar
• PSP Scale. In: Michalos AC, editor. Encyclopedia of Quality of Life and Well-Being Research. Dordrecht: Springer; 2014.
   Google Scholar
• Pinna F, Tusconi M, Bosia M, Cavallaro R, Carpiniello B; Cagliari Recovery Group Study. Criteria for symptom remission revisited: a study of patients affected by schizophrenia and schizoaffective disorders. BMC Psychiatry. 2013;26(13):235.
   Web of Science ®Google Scholar
• van Wijngaarden B, Schene AH, Koeter M, et al. Caregiving in schizophrenia: development, internal consistency and reliability of the Involvement Evaluation Questionnaire–European Version. EPSILON Study 4. European psychiatric services: inputs linked to outcome domains and needs. Br J Psychiatry Suppl. 2000;(39):s21‐s27.
   Google Scholar
• Li N, Feng Y, Lu H, et al. Factors related to improvement of symptoms, function, and caregiver burden in Chinese patients with schizophrenia after switching to paliperidone palmitate once-monthly from oral antipsychotics. Neuropsychiatr Dis Treat. 2018;14:825‐837. doi:10.2147/NDT.S158353
   Web of Science ®Google Scholar
• Altamura AC, Serati M, Buoli M. Is duration of illness really influencing outcome major psychoses? Nord J Psychiatry. 2015;69(6):403‐417. doi:10.3109/08039488.2014.990919
   Web of Science ®Google Scholar
• Haro JM, Novick D, Suarez D, et al. Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study. J Clin Psychopharmacol. 2006;26(6):571‐578. doi:10.1097/01.jcp.0000246215.49271.b8
   Web of Science ®Google Scholar
• Haro JM, Novick D, Suarez D, Ochoa S, Roca M. Predictors of the course of illness in outpatients with schizophrenia: a prospective three year study. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(5):1287‐1292.
   Web of Science ®Google Scholar
• Siegel SJ, Irani F, Brensinger CM, et al. Prognostic variables at intake and long-term level of function in schizophrenia. Am J Psychiatry. 2006;163(3):433‐441. doi:10.1176/appi.ajp.163.3.433
   Web of Science ®Google Scholar
• Schennach-Wolff R, Jäger M, Seemüller F, et al. Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders. Schizophr Res. 2009;113(2–3):210‐217.
   Web of Science ®Google Scholar
• Suresh KK, Kumar CN, Thirthalli J, et al. Work functioning of schizophrenia patients in a rural south Indian community: status at 4-year follow-up. Soc Psychiatry Psychiatr Epidemiol. 2012;47(11):1865‐1871. doi:10.1007/s00127-012-0495-8
   Web of Science ®Google Scholar
• Savla GN, Vella L, Armstrong CC, Penn DL, Twamley EW. Deficits in domains of social cognition in schizophrenia: a meta-analysis of the empirical evidence. Schizophr Bull. 2013;39(5):979‐992. doi:10.1093/schbul/sbs080
   Web of Science ®Google Scholar
• Altamura AC, Buoli M, Serati M. Duration of illness and duration of untreated illness in relation to drug response in psychiatric disorders. Neuropsychiatry. 2011;1(1):81–90. doi:10.2217/npy.10.2
   Google Scholar
• Wojtalik JA, Smith MJ, Keshavan MS, Eack SM. A systematic and meta-analytic review of neural correlates of functional outcome in schizophrenia. Schizophr Bull. 2017;43(6):1329‐1347.
   Web of Science ®Google Scholar
• Doering S, Müller E, Köpcke W, et al. Predictors of relapse and rehospitalization in schizophrenia and schizoaffective disorder. Schizophr Bull. 1998;24(1):87‐98. doi:10.1093/oxfordjournals.schbul.a033316
   Web of Science ®Google Scholar
• Lambert M, Karow A, Leucht S, Schimmelmann BG, Naber D. Remission in schizophrenia: validity, frequency, predictors, and patients’ perspective 5 years later. Dialogues Clin Neurosci. 2010;12(3):393‐407.
   Google Scholar
• Racenstein JM, Harrow M, Reed R, Martin E, Herbener E, Penn DL. The relationship between positive symptoms and instrumental work functioning in schizophrenia: a 10 year follow-up study. Schizophr Res. 2002;56(1–2):95‐103. doi:10.1016/S0920-9964(01)00273-0
   Web of Science ®Google Scholar
• Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association Practice guideline for the treatment of patients with schizophrenia (Systematic Review). Am J Psychiatry. 2020;177(9):868–872. doi:10.1176/appi.ajp.2020.17790132867516
   PubMed Web of Science ®Google Scholar
• Llorca PM, Abbar M, Courtet P, Guillaume S, Lancrenon S, Samalin L. Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness. BMC Psychiatry. 2013;13:340. doi:10.1186/1471-244X-13-34024359031
   PubMed Web of Science ®Google Scholar
• Alphs L, Bossie CA, Sliwa JK, Ma YW, Turner N. Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial. Ann Gen Psychiatry. 2011;10(1):12. doi:10.1186/1744-859X-10-1221481243
   PubMed Web of Science ®Google Scholar
• Coppola D, Liu Y, Gopal S, et al. A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia. BMC Psychiatry. 2012;12:26. doi:10.1186/1471-244X-12-2622455454
   PubMed Web of Science ®Google Scholar
• Si T, Su Y, Liu Y, et al. Pharmacokinetics and tolerability of paliperidone palmitate injection in Chinese subjects. Hum Psychopharmacol. 2014;29(2):203‐210. doi:10.1002/hup.2388
   Web of Science ®Google Scholar